Navigation Links

BEDFORD, Mass., Jan. 22, 2013 /PRNewswire/ -- Hologic, Inc. ("Hologic" or "the Company") (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced organizational changes to its Diagnostics segment. 

Based upon the successful progress achieved in the ongoing integration of Gen-Probe Incorporated ("Gen-Probe"), which is proceeding ahead of schedule, and the solid foundation of the Diagnostics segment, Hologic has accelerated the timing of several planned organizational changes. In conjunction with the Company's accelerated execution, Carl Hull will be retiring from his role as Senior Vice President and General Manager of Diagnostics. Mr. Hull, who served as Chairman, President and Chief Executive Officer of Gen-Probe until that company was acquired by Hologic in August 2012, will continue with the Company as a consultant up to mid-August 2013.

"We are confident that now is the right time to transition our team and we are grateful for the deep bench of talent within the Hologic and legacy Gen-Probe organizations who are well positioned to successfully assume greater levels of responsibility as we continue to grow," said Rob Cascella , President and Chief Executive Officer of Hologic. "Carl has been instrumental in the ongoing and successful integration of Gen-Probe into Hologic that has supported our rapid progress. We have benefitted from his experience, deep knowledge of the industry and valuable relationships and we thank Carl for his leadership and commitment. We look forward to his continued contributions throughout 2013, including his support in facilitating a seamless leadership transition."

"We have a well-defined strategic path forward to grow the diagnostics businesses globally, drive innovation and expand our technology offerings," said Mr. Hull. "I look forward to working with Rob and the rest of the team to ensure that we capture the benefits of the Gen-Probe transaction for all of our stakeholders. We are very excited about our future and are confident that today, Hologic is well positioned to build upon its leadership role in diagnostics as it continues to meet the expanding needs of its customers."

As part of the organizational changes, Rohan Hastie , formerly a vice president and general manager within the Women's Health group of the Company's Diagnostics segment, has been appointed Senior Vice President and Group General Manager - Diagnostics, which now includes overseeing the segment's Women's Health and Virology businesses, as well as the U.S. Diagnostics sales team. In addition, Eric Tardif , Senior Vice President of Commercial Operations - Diagnostics, will assume the role of Senior Vice President of Corporate Strategy, partnering with Mr. Cascella and the business leaders to further shape Hologic's long-range goals.

On Track to Achieve Over $40 Million in First-Year Cost Synergies:Hologic has made significant progress in integrating Gen-Probe into its existing Diagnostics segment. The Company remains on track to realize over $40 million in cost synergies by the end of the first year following the acquisition and an additional $35 million in cost synergies by the end of the third year. In addition, Hologic is continuing to drive revenue synergies by utilizing its global sales and marketing presence to capitalize on cross-selling opportunities to leverage its expanded molecular diagnostics product portfolio.

"Through our efforts since August, we have made tremendous strides in leveraging our global infrastructure and robust product pipeline – cementing Hologic's position as a premier provider of diagnostics solutions," continued Mr. Cascella. "The integration of Gen-Probe is proceeding at a pace better than plan. We are excited about the significant opportunities we have to create value for all of our stakeholders, including our shareholders and customers, and we are confident that these organizational changes will help take our Diagnostics franchise to the next level."

About Hologic, Inc.:Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit

Hologic, Gen-Probe and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer:This News Release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation, the anticipated benefits and synergies of the Gen-Probe acquisition and the Company's outlook and opportunities. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: Hologic's ability to successfully and timely integrate Gen-Probe's operations, product lines, technologies and employees, and realize synergies from the proposed transaction; unknown, underestimated or undisclosed commitments or liabilities, costs or expenses; the level of demand for the Company's products; the ability of the Company to develop, deliver and support a broad range of products, develop new products, expand its markets and/or develop new markets; and the ability of the Company to attract, motivate and retain key employees. Moreover, the combined business may be adversely affected by future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.Investor Relations and Media Contacts:Deborah R. Gordon

Al KildaniVice President, Investor Relations

Senior Director, Investor Relations (781) 999-7716


SOURCE Hologic, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hologic to Showcase Award Winning 3D Mammography and Other Advanced Imaging Technologies at RSNA 2012
2. Hologic Announces Fourth Quarter and Fiscal 2012 Operating Results
3. Hologic to Showcase Advancement Simplifying Removal of Large Intrauterine Pathology at AAGL
4. Hologic, Inc. Marks Breast Cancer Awareness Month by Ringing the Opening Bell at NASDAQ and Taking 3D Mammography on the Road
5. Hologic Announces Verdict In Patent Infringement Suit
6. Hologic To Participate In The Morgan Stanley Global Healthcare Conference
7. Senator Blumenthal, a Strong Advocate for Womens Health, Visits Hologics Manufacturing Facility in Danbury, CT
8. Hologic Completes Acquisition Of Gen-Probe
9. Hologic Announces Third Quarter Fiscal 2012 Operating Results
10. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
11. Hologic Human Papillomavirus (HPV) High-Risk Test Approved for Use in The Netherlands Population Cervical Screening Programme
Post Your Comments:
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... 24, 2015 --> ... MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... grow at the fastest rates? This visiongain ... trends, opportunities and prospects there. ,  ,Our 199-page report ... lucrative areas in the industry and the future market ...
(Date:11/24/2015)... Inc., an industry leader in LCD screen protection and glare-elimination technology, is providing a vital solution ... patient monitoring or electronic documentation system. Photo - ... ... ... A study in 2013 by the National Institutes of ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... PLAINSBORO, N.J. (PRWEB) , ... November 24, 2015 ... ... experts will gather to share their knowledge and experiences at a live taping ... during the Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at ...
(Date:11/24/2015)... ... 24, 2015 , ... Aided by seed funding from the Ron Foley Foundation, ... yield insights into how to detect and treat pancreatic cancer (PC). , WCHN ... non-coding RNA molecules (ncRNA), genetic material that is present in the blood of patients ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore ... TrustDale certification. The award recognizes good companies for excellence in service and a ... grout, and hard surface restoration company earned this recognition after a thorough review ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Innovative Blending, a household invention that revolutionizes the vending ... Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO ...
Breaking Medicine News(10 mins):